- Frova
-
- $1.80 / 1KG
-
2020-03-22
- CAS:158930-17-7
- Min. Order: 1g
- Purity: 90.0%-99.9%
- Supply Ability: 800kg
|
| Product Name: | Frova | | Synonyms: | Frova;(3R)-2,3,4,9-Tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide Butanedioic Acid Monohydrate;Frovatriptan Succinate Monohydrate;Frovelan;Migard;Miguard;1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (R)-, butanedioate (1:1), monohydrate;Butanedioic acid, compd. with (R)-2,3,4,9-tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide (1:1), monohydrate | | CAS: | 158930-17-7 | | MF: | C18H25N3O6 | | MW: | 0 | | EINECS: | | | Product Categories: | Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 158930-17-7.mol |  |
| | Frova Chemical Properties |
| Melting point | 150-153°C | | storage temp. | 2-8°C | | solubility | DMSO (Slightly), Methanol (Slightly, Heated), Water (Slightly, Heated) | | form | powder | | color | white to beige | | Water Solubility | H2O: 20mg/mL, clear | | CAS DataBase Reference | 158930-17-7 |
| | Frova Usage And Synthesis |
| Chemical Properties | White to Off-White Powder | | Uses | Serotonin 5-HT1B/1D receptor agonist. It is a triptan drug for the treatment of migraine headaches. Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. | | Brand name | Frova (Endo). | | Biochem/physiol Actions | Frovatriptan is a serotonin 5HT-1B/1D-receptor agonist used to treat migraine. Frovatriptan has high affinity for the 5-HT(1B) and 5-HT(1D) receptors while affinity for 5-HT receptors other than 5-HT(1B/1D) is substantially lower with a pEC50 value of 8.2 for the 5-HT1B receptor, compared to a pEC50 value of 6.2 for the 5-HT7 receptor. | | in vivo | Oral bioavailability of Frovatriptan is 22%-30% and is not affected by food. Although the maximum concentration in the plasma is achieved in 2-3 hours, 60%-70% of this is achieved in 1 hour. A steady state is achieved in 4-5 days. Plasma protein binding is low at 15%. The most unique feature is the relative terminal long half-life of about 26 hours. Frovatriptan is chiefly metabolized by CYP1A2 and is cleared by the kidney and liver making moderate failure of either organ not a limiting factor in treatment[1].
Frovatriptan (0.1, 0.2, and 0.3 mg/kg; a single bolus intraduodenal administration) treatment produces an increase in carotid vascular resistance, which is sustained for at least 5 hours in dogs[2]. | | IC 50 | 5-HT1B Receptor: 8.2 (pEC50); 5-HT1D Receptor |
| | Frova Preparation Products And Raw materials |
|